---
title: "BioMarin Secures $2 Billion Term Loan to Fund Amicus Therapeutics Acquisition"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274202263.md"
datetime: "2026-01-29T21:07:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274202263.md)
  - [en](https://longbridge.com/en/news/274202263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274202263.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274202263.md) | [English](https://longbridge.com/en/news/274202263.md)


# BioMarin Secures $2 Billion Term Loan to Fund Amicus Therapeutics Acquisition

BioMarin Pharmaceutical Inc. has completed the syndication of a new $2 billion senior secured term loan B facility, in addition to an $800 million term loan A facility, as part of its pending acquisition of Amicus Therapeutics, Inc. The financing package also includes a $600 million senior secured revolving credit facility expected to be entered into in connection with the acquisition. Additionally, BioMarin has priced a $850 million offering of 5.500% senior unsecured notes due 2034 at par. The proceeds from these transactions, along with cash on hand, are intended to fund the consideration for the acquisition of Amicus Therapeutics and related expenses. The closing of the notes offering is expected on February 12, 2026, subject to customary closing conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF74559) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Amicus Therap (FOLD.US)](https://longbridge.com/zh-HK/quote/FOLD.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BioMarin Pharma (BMRN.US)](https://longbridge.com/zh-HK/quote/BMRN.US.md)

## 相關資訊與研究

- [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/zh-HK/news/279015256.md)
- [Cipher Pharmaceuticals Delivers Record 2025 Results and Primes for Next Acquisition Phase](https://longbridge.com/zh-HK/news/278950215.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/zh-HK/news/278778570.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-HK/news/278776483.md)
- [13:06 ETHall Render Represents Centurion Foundation in Rhode Island Hospital Acquisition, Preserving Essential Health Care Services](https://longbridge.com/zh-HK/news/278427087.md)